MarketCapExport financials
Sigilon Therapeutics (SGTX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Sigilon Therapeutics Balance Sheet 2022-2011 | SGTX
Brief balance sheet overview of Sigilon Therapeutics
Balance sheet changes are traced across five available annual reports between 2018 and 2022.
The balance sheet expanded from $67.7 million to $87.3 million. Growth of +29% and CAGR of 6.6% look measured and sustainable.
Growth in the asset base was not matched by liabilities: +29% versus -53.6%. The balance sheet moved in a more conservative direction.
Equity finances 44.8% of the balance sheet, compared with at the start. The cushion remains adequate.
Net debt moved below zero to -$25.6 million, reflecting surplus cash over debt.
Retained earnings remain negative at -$256.8 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Balance sheet takeaway
Sigilon Therapeutics's financial position is positive on balance sheet evidence. Growth in resources has not undermined capital strength.
Annual Balance Sheet Sigilon Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-25.6 M | -83.9 M | -177 M | -51 M | -59.1 M | - | - | - | - | - | - | - |
Long Term Debt |
12 M | 18.4 M | 19.8 M | 14.9 M | 4.29 M | - | - | - | - | - | - | - |
Long Term Debt Current |
4.48 M | 4.84 M | 5.36 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 31.9 M | 128 M | 74.6 M | - | - | - | - | - | - | - |
Total Current Liabilities |
31 M | 34.9 M | 47 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
48.1 M | 67.2 M | 78.9 M | 168 M | 104 M | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | 31.8 M | 29.1 M | 24.7 M | - | - | - | - | - | - | - |
Retained Earnings |
-257 M | -213 M | -136 M | -81.3 M | -37.4 M | - | - | - | - | - | - | - |
Total Assets |
87.3 M | 144 M | 225 M | 90.4 M | 67.7 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
42.1 M | 107 M | 202 M | - | - | - | - | - | - | - | - | - |
Book Value |
39.1 M | 77.2 M | 146 M | -77.8 M | -36.1 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
39.1 M | 77.2 M | 146 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Sigilon Therapeutics
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
12 M | 10.4 M | 12 M | 13.6 M | 15.2 M | 16.8 M | 18.4 M | 20 M | 20 M | 20 M | 19.8 M | 20 M | 20 M | 20 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
28.1 M | 43.3 M | 48.1 M | 50.2 M | 55.6 M | 61.6 M | 67.2 M | 70.5 M | 75.1 M | 74.4 M | 78.9 M | 78.9 M | 78.9 M | 78.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-272 M | -264 M | -257 M | -250 M | -241 M | -227 M | -213 M | -195 M | -175 M | -155 M | -136 M | -136 M | -136 M | -136 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
55.6 M | 76.6 M | 87.3 M | 94.6 M | 107 M | 126 M | 144 M | 164 M | 186 M | 203 M | 225 M | 225 M | 225 M | 225 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
19.6 M | 41.3 M | 42.1 M | 32.9 M | 34.5 M | 64.5 M | 107 M | 140 M | 162 M | 179 M | 202 M | 202 M | 202 M | 202 M | 76.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
27.4 M | 33.3 M | 39.1 M | 44.4 M | 51.8 M | 64.6 M | 77.2 M | 93.3 M | 111 M | 129 M | 146 M | 146 M | 146 M | 146 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
27.4 M | 33.3 M | 39.1 M | 44.4 M | 51.8 M | 64.6 M | 77.2 M | 93.3 M | 111 M | 129 M | 146 M | 146 M | 146 M | 146 M | -77.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Sigilon Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Schweiz
USA
Israel
China
Canada
Britain
Russia
